Mathias Witzens‐Harig

5.8k total citations
136 papers, 2.8k citations indexed

About

Mathias Witzens‐Harig is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Mathias Witzens‐Harig has authored 136 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Pathology and Forensic Medicine, 63 papers in Oncology and 44 papers in Genetics. Recurrent topics in Mathias Witzens‐Harig's work include Lymphoma Diagnosis and Treatment (82 papers), Chronic Lymphocytic Leukemia Research (40 papers) and Viral-associated cancers and disorders (29 papers). Mathias Witzens‐Harig is often cited by papers focused on Lymphoma Diagnosis and Treatment (82 papers), Chronic Lymphocytic Leukemia Research (40 papers) and Viral-associated cancers and disorders (29 papers). Mathias Witzens‐Harig collaborates with scholars based in Germany, United States and France. Mathias Witzens‐Harig's co-authors include Anthony D. Ho, Hartmut Goldschmidt, John G. Gribben, Patrick Wuchter, Kai Neben, Andreas Trojan, Martin Dreyling, Thomas Brückner, Angela M. Krackhardt and Sabine Harig and has published in prestigious journals such as Circulation, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Mathias Witzens‐Harig

133 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mathias Witzens‐Harig Germany 30 1.3k 1.1k 895 738 665 136 2.8k
Timothy S. Fenske United States 27 1.7k 1.3× 1.2k 1.1× 522 0.6× 624 0.8× 543 0.8× 162 2.6k
Monica Bocchia Italy 28 1.0k 0.8× 850 0.8× 964 1.1× 1.1k 1.4× 1.3k 1.9× 179 2.9k
Loïc Ysebaert France 33 1.5k 1.2× 1.7k 1.5× 1.2k 1.3× 1.1k 1.5× 398 0.6× 139 3.7k
Amanda F. Cashen United States 29 1.0k 0.8× 1.4k 1.2× 445 0.5× 549 0.7× 891 1.3× 121 2.9k
Anne Tierens Norway 29 778 0.6× 914 0.8× 572 0.6× 659 0.9× 590 0.9× 101 2.2k
Barbara Bigerna Italy 23 664 0.5× 929 0.8× 661 0.7× 555 0.8× 692 1.0× 35 2.5k
Nilanjan Ghosh United States 28 1.4k 1.1× 939 0.8× 701 0.8× 424 0.6× 386 0.6× 160 2.4k
Elena Hartmann Germany 26 992 0.8× 1.5k 1.3× 619 0.7× 1.1k 1.5× 276 0.4× 80 2.6k
Eva Giné Spain 32 1.4k 1.1× 2.0k 1.8× 662 0.7× 1.4k 1.9× 461 0.7× 107 3.0k
Scott Ely United States 28 1.6k 1.3× 1.1k 1.0× 674 0.8× 737 1.0× 872 1.3× 89 3.4k

Countries citing papers authored by Mathias Witzens‐Harig

Since Specialization
Citations

This map shows the geographic impact of Mathias Witzens‐Harig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mathias Witzens‐Harig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mathias Witzens‐Harig more than expected).

Fields of papers citing papers by Mathias Witzens‐Harig

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mathias Witzens‐Harig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mathias Witzens‐Harig. The network helps show where Mathias Witzens‐Harig may publish in the future.

Co-authorship network of co-authors of Mathias Witzens‐Harig

This figure shows the co-authorship network connecting the top 25 collaborators of Mathias Witzens‐Harig. A scholar is included among the top collaborators of Mathias Witzens‐Harig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mathias Witzens‐Harig. Mathias Witzens‐Harig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Heß, Georg, Andreas Hüttmann, Mathias Witzens‐Harig, et al.. (2022). A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial. British Journal of Haematology. 198(3). 482–491. 4 indexed citations
2.
Kaddu‐Mulindwa, Dominic, Christian Berdel, Stephan Stilgenbauer, et al.. (2021). Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial. Leukemia & lymphoma. 63(2). 326–334. 2 indexed citations
3.
4.
Kriegsmann, Katharina, Mark Kriegsmann, & Mathias Witzens‐Harig. (2018). Acalabrutinib, A Second-Generation Bruton’s Tyrosine Kinase Inhibitor. Recent results in cancer research. 212. 285–294. 16 indexed citations
5.
6.
Zhou, Xiang, Katharina Lisenko, Nicola Lehners, et al.. (2017). The influence of rituximab-containing chemotherapy on HCV load in patients with HCV-associated non-Hodgkin’s lymphomas. Annals of Hematology. 96(9). 1501–1507. 4 indexed citations
7.
Lehners, Nicola, et al.. (2017). Prognostic Impact of Extranodal Involvement in Newly Diagnosed Diffuse Large B-Cell Lymphoma. Blood. 130. 2855–2855. 1 indexed citations
8.
Lisenko, Katharina, Sandra Sauer, Thomas Brückner, et al.. (2017). High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting. BMC Cancer. 17(1). 151–151. 14 indexed citations
9.
Lisenko, Katharina, Martin Cremer, Mark Kriegsmann, et al.. (2016). Efficient stem cell collection after modified cisplatin-based mobilization chemotherapy in patients with DLBCL. Oncology Research and Treatment. 1 indexed citations
10.
Lisenko, Katharina, Petra Pavel, Mark Kriegsmann, et al.. (2016). Storage Duration of Autologous Stem Cell Preparations Has No Impact on Hematopoietic Recovery after Transplantation. Biology of Blood and Marrow Transplantation. 23(4). 684–690. 23 indexed citations
11.
Textor, Sonja, Felicitas Bossler, Kai-Oliver Henrich, et al.. (2016). The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells. OncoImmunology. 5(7). e1116674–e1116674. 42 indexed citations
12.
Pfreundschuh, Michael, Viola Poeschel, Samira Zeynalova, et al.. (2014). Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group. Journal of Clinical Oncology. 32(36). 4127–4133. 59 indexed citations
13.
Schmitt, Michael, Patrick Wuchter, Eike C. Buss, et al.. (2014). Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma. Transfusion. 55(2). 275–283. 33 indexed citations
14.
Murawski, Niels, Michael Pfreundschuh, Samira Zeynalova, et al.. (2014). Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL. Annals of Oncology. 25(9). 1800–1806. 48 indexed citations
15.
Blank, Norbert, Hanns‐Martin Lorenz, Anthony D. Ho, & Mathias Witzens‐Harig. (2014). Sarcoidosis and the occurrence of malignant diseases. Rheumatology International. 34(10). 1433–1439. 23 indexed citations
16.
Witzens‐Harig, Mathias, Manfred Hensel, Michael Unterhalt, & Klaus Herfarth. (2011). Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial. BMC Cancer. 11(1). 87–87. 20 indexed citations
17.
Witzens‐Harig, Mathias, Thomas Moehler, Kai Neben, et al.. (2004). Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide. Annals of Hematology. 83(7). 467–470. 6 indexed citations
18.
Witzens‐Harig, Mathias, et al.. (2001). Successful Treatment of Bronchiolitis obliterans Organizing Pneumonia with Low-Dose Methotrexate in a Patient with Hodgkin’s Disease. Oncology. 61(1). 23–27. 9 indexed citations
19.
Trojan, Andreas, Joachim L. Schultze, Mathias Witzens‐Harig, et al.. (2000). Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nature Medicine. 6(6). 667–672. 139 indexed citations
20.
Witzens‐Harig, Mathias, et al.. (1998). A case of μ heavy-chain disease associated with hyperglobulinemia, anemia, and a positive Coombs test. Annals of Hematology. 77(5). 231–234. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Timothy S. Fenske Breakdown of academic impact, for papers by Monica Bocchia Breakdown of academic impact, for papers by Loïc Ysebaert Breakdown of academic impact, for papers by Amanda F. Cashen Breakdown of academic impact, for papers by Anne Tierens Breakdown of academic impact, for papers by Barbara Bigerna Breakdown of academic impact, for papers by Nilanjan Ghosh Breakdown of academic impact, for papers by Elena Hartmann Breakdown of academic impact, for papers by Eva Giné Breakdown of academic impact, for papers by Scott Ely
Rankless by CCL
2026